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Abstract 
Genome-wide association studies (GWAS) have focused primarily on populations of European 
descent, but it is essential that diverse populations become better represented. Increasing 
diversity among study participants will advance our understanding of genetic architecture in all 
populations and ensure that genetic research is broadly applicable. To facilitate and promote 
research in multi-ancestry and admixed cohorts, we outline key methodological considerations 
and highlight opportunities, challenges, solutions, and areas in need of development. Despite the 
perception that analyzing genetic data from diverse populations is difficult, it is scientifically and 
ethically imperative, and there is an expanding analytical toolbox to do it well. 
 
 
Keywords: GWAS; ancestry; diversity; cross-ancestry; trans-ancestry; trans-ethnic; population 
genetics; admixed populations; psychiatry; complex disease.  
 
 
Main Text 
A disproportionate majority (>78%) of participants in published genome-wide association 
studies (GWAS) are of European descent (Popejoy and Fullerton, 2016; Sirugo et al., 2019), 
with 71.8% of these individuals having been recruited from just three countries: the United 
States, the United Kingdom, and Iceland (Mills and Rahal, 2019). Studies of major psychiatric 
disorders are no exception, having focused largely on populations of European ancestry (Figure 
1). Conducting GWAS in individuals of European ancestry was a practical starting point given 
the availability of samples and limited funding, genotyping technologies, and analytic methods. 
However, there is now widespread acknowledgement of the need for more diverse samples and 
for improved analytic methods. Broadening diversity of studied populations will improve the 
effectiveness of genomic medicine by expanding the scope of known human genomic variation 
and bolstering our understanding of disease etiology. Consensus in the field points to many 
benefits of increased representation of more diverse populations for locus discovery, fine-
mapping, polygenic risk scores, and addressing existing health disparities (Duncan et al., 2018; 
Hindorff et al., 2018a; Lam et al., 2018; Martin et al., 2019; Walters et al., 2018).  
With increasing representation of global populations in GWAS, there is an opportunity 
for advanced methods development and a need for consensus "best practices" for analyzing the 
emerging complex datasets. Here, we provide background on the scientific and ethical 
importance of including underrepresented groups in genetics research and offer guidance for 
whole-genome analysis of ancestrally diverse study cohorts. We summarize currently available 
resources and make recommendations for avoiding practices that could lead to false-positives, 
loss of statistical power, or misinterpretation of results. Because this primer represents a 
collaborative product of the Cross-Population Special Interest Group of the Psychiatric 
Genomics Consortium (PGC) (https://www.med.unc.edu/pgc/cross-population/), we have framed 
our discussion within the context of psychiatric genetics. Nevertheless, the points and 
recommendations outlined herein are applicable to any complex biomedical phenotype.  
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Figure 1.  Diversity in GWAS of psychiatric disorders compared to global diversity. 
Participant numbers were extracted from the largest consortium publication(s) for each 
psychiatric disorder and are shown as fractions of the total sample size for each disorder.  
 
 
 
Note: Sample sizes are given in parentheses. Numbers reflect cases and controls combined. 
MD=major depression (490,999), SCZ=schizophrenia (205,661), PTSD=post-traumatic stress 
disorder (188,932), BIP=bipolar disorder (51,710), ADHD=attention deficit hyperactivity 
disorder (55,230), AUT=autism (46,350), AD=alcohol dependence (52,848), AN=anorexia 
(14,477). *For schizophrenia, the African American samples from an earlier publication (2009, 
International Schizophrenia Consortium) were not included in the most recent PGC 
schizophrenia publication (2014). Ancestry information for each participant was based on 
principal components analysis of genetic data. See Supplemental Table S1 for consortium 
studies and references.  
 
 
Genetic ancestry is estimated from DNA and provides information about shared 
demographic history at the population level. Individuals with similar ancestral origins have 
shared genomic signatures due to migration of common ancestors, mutations and recombination, 
genetic drift, and natural selection. These processes yield differences in allele frequencies and 
linkage disequilibrium (LD) patterns across populations (Barrett and Cardon, 2006; International 
HapMap Consortium, 2005) that must be properly addressed to avoid false positive genetic 
findings. In addition to ancestral diversity, the current lack of racial and ethnic diversity, which 
are related but distinct from ancestry (see Box 1), hinder the development of more complete 
etiological models (Banda et al., 2015; Medina-Gomez et al., 2015; Race, Ethnicity, and 
Genetics Working Group, 2005). In complex disease research, race and ethnicity can provide 
information about social, cultural, and environmental factors that affect risk for disease, 
including having a lived experience of social injustice. Given that these socio-cultural measures 
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are often inappropriately used as a proxy for genetic ancestry, researchers and clinicians should 
be careful to distinguish among them in order to tease apart specific biological, environmental, 
and social determinants of health. 
  
 
Box 1: Race, Ethnicity, and Ancestry: Interpretation and Relevance for Genetic Diversity. 
‘Race’, ‘ethnicity’ and ‘ancestry’ are often used interchangeably, yet they have no universal definitions. 
We provide brief descriptions of our usage below. For extensive discussion in the context of genomics, 
including recommendations from professional organizations see: (Banda et al., 2015; Mersha and Abebe, 
2015; Race, Ethnicity, and Genetics Working Group, 2005).  
Race 
 
Race 
A culturally and politically charged term, for which definitions and meaning are context-
specific. Race is related to individual and/or group identity, and is often linked to 
stereotypes of visible physical attributes such as skin and hair pigmentation. The concept of 
‘race’ is tightly linked to social power dynamics and has historically been used to justify 
hierarchies of power, discrimination, and oppression in an unequal society. Social and 
cultural conditions may differ among racial groups, on average, and these differences may 
lead to environmental effects such as chronic stress and unequal access to goods and 
services including healthcare and nutrition. These inequities can affect environmental risk 
for complex diseases and/or potentially interact with genetics to affect risk.  
Ethnicity 
 
 
Ethnicity 
Describes people as belonging to cultural groups, usually on the basis of shared language, 
traditions, foods, etc. Ethnicity has often been used interchangeably with ‘race,’ and is 
similarly ambiguous. To the extent that traits are affected by social and environmental 
differences, ‘ethnicity’ has previously served as a proxy for health and disease risk at the 
population level as a result of social, cultural, and community effects described above. 
There is no universal agreement on a system of ‘ethnic’ groupings worldwide. Some 
‘ethnic’ groups may share genetic factors due to similar ancestral origins, other groups may 
be more social and cultural in nature. 
Ancestry 
 
 
 
Ancestry 
Meaning varies by context. Here we use the term to denote genetic ancestry, a description 
of the population(s) from which an individual’s recent biological ancestors originated, as 
reflected in the DNA inherited from those ancestors. Genetic ancestry can be estimated 
via comparison of participants’ genotypes to global reference populations, so incomplete 
availability of these references can create biased estimates. We note that different 
methods of calculating genetic ancestry can yield different results. Thus, discrete labelling 
of ancestral populations over-simplifies the complexity of human genetic variation and 
demography. Nevertheless, accounting for systematic differences in allele frequencies and 
LD is necessary for genetic analyses. In this paper, diversity in genomics is described 
primarily in terms of ‘ancestry’. 
 
Inclusion of diverse study participants in genomics research has yielded important 
scientific insights for a range of human traits and diseases. The resolution of fine-mapping 
improves through cross-ancestry analysis (Wojcik et al., 2019). Estimates of effect-sizes derived 
from cohorts of diverse ancestries tend to be more accurate than from those of a single ancestry 
(Li and Keating, 2014). Genetic risk prediction attenuates with increasing divergence between 
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the discovery and target populations, indicating that polygenic risk scores (PRS) based on 
Eurocentric GWAS are not equally predictive when applied to non-European populations 
(Duncan et al., 2018; Martin et al., 2019). Conversely, constructing individual-level scores from 
cross-ancestry meta-analysis results improves overall prediction (Grinde et al., 2019; Márquez-
Luna et al., 2017).  
Besides the strong scientific justifications for broader inclusion, there are important 
ethical, legal, and public health reasons for bolstering diversity in genomics (Hindorff et al., 
2018b). Understanding how genetic risk and social inequities interact to influence disparities in 
disease risk and outcomes will be critical to improving public health.  
Moreover, while integration of genomics into healthcare has the potential to improve disease 
prediction and optimize treatments, a lack of diversity will limit the utility of precision medicine 
efforts: individuals of non-European descent are more likely to receive ambiguous test results 
from genetic screening (e.g., variants of unknown or uncertain significance) (Petrovski and 
Goldstein, 2016) and false positive diagnoses (Manrai et al., 2016). There is also a higher chance 
of false negative diagnoses in individuals from ancestral backgrounds that are not well 
represented in clinical databases, due to missing information about additional disease-causing 
variants currently not on testing panels (Minster et al., 2016; Moltke et al., 2014; Wheeler et al., 
2017). Similarly, the potential benefits of pharmacogenetics cannot be fully realized until there is 
equitable representation across ancestries, as some therapeutics may be more effective and/or 
safer in certain populations because of differences in allele frequency, effect size, and penetrance 
of variants associated with drug metabolism (Roden et al., 2011). Here, we provide an accessible 
framework for analyzing these data, while acknowledging that there are several important 
methodological areas in need of further development. Key terminology is bolded and defined in 
Box 2.  
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Box 2: General Terminology. 
Term Definition/Comment 
Admixed 
Population 
A population of individuals with ancestors from two or more populations. Admixed can also be used to refer 
to individuals. 
Fine-mapping 
Analytical procedures designed to refine GWAS loci to a smaller set of likely causal variant candidates to 
facilitate interpretation and follow-up studies. 
Genetic 
Correlation 
The correlation of genome-wide genetic effects between two phenotypes, which is often estimated for a subset 
of genomic variants (e.g. SNPs in a GWAS).  
Genotype 
Imputation 
Estimation of genotypes at genetic sites that have not been directly measured, using data from a reference 
panel to infer genotypes based on LD and haplotype structures. Accuracy depends on availability of suitable 
reference panels. 
GWAS 
Genome-wide association study. Analysis of common genetic variants across the whole genome for 
association with a phenotype.   
GxE 
Gene by environment interaction refers to genetic effects on a phenotype that vary based on environment, or 
vice-versa. 
Haplotype A group of alleles that are correlated with one another because they are inherited together on a chromosome.  
HWE 
Hardy-Weinberg equilibrium, the expected balance of genotypes within a population assuming random 
mating, infinite population size, and no mutation, migration, or selection. Tests of deviations from HWE are 
used in quality control to detect technical issues with genotyping. Note that there are also non-technical 
reasons for deviation from HWE (e.g., selection, population structure, admixture, nonrandom mating).  
LD 
Linkage disequilibrium. Alleles in LD are physically linked on a chromosome, which leads to non-random 
coinheritance such that their frequencies in a population are correlated.  
Major 
Population 
A group of individuals with shared genetic ancestry. A heuristic simplification of the complexity of human 
demography, but useful for describing groups that are likely to have relatively similar allele frequencies and 
LD patterns due to shared ancestry. Common examples used in practice include continental ancestry groups or 
“super populations” as defined by the 1000 Genomes Project (e.g., African, Admixed American, East Asian). 
PCA 
Principal component analysis. PCA of genotype data is commonly used to examine population structure in a 
cohort by determining the average genome-wide genetic similarities of individual samples. Derived PCs can 
be used to group individuals with shared genetic ancestry, identify outliers, and as covariates to reduce false 
positives due to population stratification. 
Population 
Stratification 
Underlying population structure within a sample that is correlated with a phenotype, which can confound 
genetic association tests.  
PRS 
Polygenic risk score. A value computed from an individual’s genotype data that quantifies genetic influences 
on a particular phenotype; also known as polygenic score (PGS), genetic risk score (GRS), or risk profile score 
(RPS).  
Reference 
Panel 
A set of genetic variants from a population. Reference panels are used to design arrays, impute genotypes, 
catalogue genetic variants, and identify regions that are similar and different between populations.  
SNP 
Heritability 
Proportion of phenotypic variance that is explained by additive genetic effects of a set of SNPs.  
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Methodological Considerations  
 
In the analysis of multi-ancestry datasets, a significant concern is false positive genetic signals 
due to inflated test statistics from population stratification, which occurs when disease 
prevalence and allelic frequency differences are correlated within or between study cohorts 
(Marchini et al., 2004). Two typical strategies exist for addressing this challenge while analyzing 
samples from multiple major/admixed populations: (1) Empirically assign samples to major 
continental and/or admixed populations using genome-wide data, analyze each population 
separately, and conduct cross-ancestry meta-analysis (stratified meta-analysis approach), and (2) 
analyze samples from multiple populations together, most commonly with a mixed model (joint 
mixed model approach). The choice between these approaches is perhaps the most broadly 
impactful decision currently facing analysts of genome-wide data from multiple populations 
since it impacts methodological considerations in all analysis steps from quality control, to 
reference alignment in imputation, to association model, to the suitability of results for secondary 
analyses. We highlight elements of GWAS where the choice between the stratified meta-analysis 
and joint mixed model approaches is particularly salient. Figure 2 shows a general workflow for 
each approach.  
 
 
I. Genotyping Technologies 
 
Most genome-wide DNA microarrays were designed for individuals of European ancestry. The 
differences in LD structure and allele frequency among populations can lead to significantly 
worse coverage for other ancestry groups. For example, at imputation accuracy r20.8, the 
Affymetrix UK Biobank array covers 84% of the variants that have minor allele frequencies 
(MAF) > 1% in samples of European ancestry but only 46% of those for samples of African 
ancestry (Nelson et al., 2017). The large genetic diversity in African populations means that a 
larger number of variants are needed on arrays in order to provide similar coverage as in other 
populations (Barrett and Cardon, 2006). To address this issue, some groups, such as China 
Kadoorie Biobank (Chen et al., 2011), have designed population-specific arrays. Multi-ancestry 
arrays, such as the Multi-Ethnic Global Array (MEGA), Global Screening Array (GSA), and the 
H3Africa array (Mulder et al., 2018) were designed based on panels with more diverse 
ancestries, and are therefore recommended. An alternative strategy is to sequence whole 
genomes; low-depth sequencing has received recent attention for application in diverse samples 
due to cost-effectiveness and higher coverage with acceptable error rates ((Gilly et al., 2018; 
Peterson et al., 2017a); see Rare Variants). 
 
 
II. Quality Control 
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Quality control (QC) of GWAS data aims to remove low quality data and technical artifacts in 
order to reduce the risk of false positive associations. In diverse ancestry cohorts, the main issue 
is that many common QC criteria assume the sample comes from a homogeneous population. 
Applying standard QC procedures without adjustment for population structure leads to the 
erroneous removal of too many variants and samples from minority subgroups and admixed 
samples, reducing statistical power.  
QC criteria that are dependent on population allele frequencies can generally be adapted 
for application in diverse cohorts by either stratifying the cohort into major populations prior to 
filtering (the stratified meta-analysis approach) or by adjusting the QC measure to allow for 
varying allele frequencies (the joint mixed model approach; see Figure 2). For example, 
individuals are often removed based on excess autosomal heterozygosity, as a potential 
indication of sample contamination, but the standard heterozygosity statistic assumes each 
variant’s expected allele frequency is constant across individuals. In diverse cohorts, regressing 
this heterozygosity statistic on principal components prior to identifying outliers can avoid 
excessive exclusions of individuals from subgroups in the cohort. Step-by-step considerations for 
common QC criteria, including sample QC workflows for the stratified meta-analysis and joint 
mixed model approaches, are given in Supplemental Methods I (see also Supplemental Table 
S2, Supplemental Figure 1). In addition to these pre-imputation QC steps, post-imputation QC 
steps should also consider ancestry (see Imputation).  
 
 
III. Inferring Population Structure 
 
Estimating the genetic population structure of a cohort typically serves two primary goals in 
GWAS: 1) to characterize the ancestral diversity of the cohort as a descriptive measure and 2) to 
provide a quantitative estimate of population structure that can be used in QC and in GWAS 
association models to reduce the risk of false positives. We focus here on use for description and 
QC, and later discuss methods for controlling for population structure (see Genome-wide 
Association). 
For cohorts with diverse ancestral backgrounds, we can estimate population structure 
based on genome-wide data. Currently the most common tool for estimating continuous 
population structure is principal component analysis (PCA); a listing of other approaches is 
included in Supplemental Methods II. PCA is a statistical method for reducing the complexity 
of high-dimensional data (e.g., thousands of measured variants across the genome) into 
orthogonal axes (principal components, PCs) that explain the largest fraction of variability in the 
data. The spread of data across these axes provides a visual guide to sub-structure among 
samples; when data points are estimated from each individual’s genetic markers, the PCs 
illustrate population structure. These PCs can be computed within the cohort, or can be estimated 
from an external reference (e.g., The 1000 Genomes Project (1KGP); (Sudmant et al., 2015)) and 
the GWAS sample can be projected onto the PC axes to allow comparison with the ancestries of 
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known reference populations (Peterson et al., 2017b). However, the latter approach can be 
limited by the number and diversity of populations represented on the reference panel, 
highlighting the need for many additional diverse population references to be generated. PCs 
may also be used to control for ancestry structure in other QC metrics (see Quality Control and 
Supplemental Table S2).  
This sample-wide estimation and visualization of genetic ancestry can be used to 
empirically assign genetically similar samples into more homogenous groups. This assignment is 
necessary for the stratified meta-analysis approach to GWAS of diverse cohorts, and is intended 
to reduce the risk of false positive genetic signals due to inflated test statistics from population 
stratification. Assigning samples to more homogeneous groups for analysis reduces 
stratification by limiting the degree of population structure remaining in the sample. Samples 
with a specific admixture can be assigned into their own major ancestral group, instead of being 
excluded from the analysis or forced into other ancestry groups, provided there are adequate 
numbers of individuals in the sample with comparable admixed backgrounds. However, it is 
often the case that genomic outliers (which tend to be from under-represented or admixed 
backgrounds) might need to be excluded if there is an insufficient number of other individuals 
who fall into a similar cluster. These assignment methods will not provide - and are not intended 
to provide - detailed ancestral background information for each individual. Rather, they provide 
a working solution to reduce false positives due to population stratification (Hellwege et al., 
2017). We stress that sample group assignment and identifying appropriate reference population 
panels can be difficult, particularly for admixed ancestry, thus requiring careful inspection of 
data and methods (Medina-Gomez et al., 2015).  
 
 
IV: Imputation and Population Reference Panels 
 
GWAS arrays genotype a portion of common variation. Genotype imputation is a cost-effective 
computational approach for inferring genotypes or genotype probabilities at variants that have 
not been directly genotyped on GWAS arrays, based on comparisons to genetic data from 
external reference samples. Imputation increases the number of markers available for association 
testing and can harmonize cohorts genotyped on different arrays for meta-analysis.  
Imputation accuracy relies on having an appropriate reference panel that includes 
haplotypes from the population studied. Matching alleles and allele frequencies in the study 
cohort with reference panels as part of pre-imputation QC also relies on using reference data 
from a matched ancestral background. Reference panels with better coverage of haplotypes from 
the population of the genotyped cohort will yield a greater number of well-imputed variants for 
GWAS, especially among lower frequency variants (Ahmad et al., 2017; Howie et al., 2012). 
Table 1 lists major imputation panels that are currently publicly available. We note that although 
many ongoing projects are aiming at more diverse populations (Supplemental Table S3), 
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additional efforts in more populations are needed to expand the diversity of imputation reference 
panels (Kelleher et al., 2018).  
Current imputation methods are summarized in Supplemental Methods III. Joint 
imputation using the largest applicable reference panel is expected to perform at least as well as 
subsetting that reference panel to match the target population (Ahmad et al., 2017; Howie et al., 
2012), possibly due to maintaining a larger sample size for phasing. Use of the same reference 
panel for all cohorts also avoids potential confounding with varying imputation quality. 
However, it may be necessary to consider imputation quality separately within subsets of 
individuals even if the samples are jointly imputed since imputation accuracy for a variant may 
vary widely across individuals of different ancestries. 
 
 
Table 1: Listing of currently available imputation reference panels. 
Reference Panels Haplo- 
types 
Ancestries Sites Availability 
TOPMed 125,568 African 32%, Asian 10%, 
European 40%, Hispanic 16% 
463,000,000 forthcoming 
Haplotype Reference 
Consortium (HRC; 
Version 1.1 2016) 
64,940 predominantly European 39,635,008 *, ** 
African Genome 
Resources 
9,912 African populations + 1000 
Genomes Project 
93,421,145 ** 
UK10K 7,562 British population 24,128,798 ** 
1000 Genomes Project 
Phase 3 (version 5) 
5,008 African 26%, Admixed 
American 14%, East Asian 
20%, European 20%, South 
Asian 20% 
85,167,453 *, **, 
mathgen.stats.ox.ac.uk/impute  
Consortium on Asthma 
among African-ancestry 
Populations in the 
Americas (CAAPA) 
1766 Admixed African populations 31,163,897 
(autosomes 
only) 
* 
Genome of the 
Netherlands (GoNL) 
998 Dutch population ~20,000,000 nlgenome.nl 
Note: *available via Michigan imputation server (https://imputationserver.sph.umich.edu). **available 
via Sanger imputation server (https://imputation.sanger.ac.uk). A listing of ongoing projects for 
imputation panels can be found in Supplemental Table S3. 
 
 
V: Genome-wide Association 
 
The core of GWAS analysis is testing the association between each variant and a target 
phenotype. As noted, a primary consideration for association testing in diverse cohorts is 
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whether to stratify samples into major population groups or to analyze the full cohort jointly 
(assuming imputation was also done jointly). In either case, the major concern is proper control 
of population stratification to ensure that observed associations reflect genetic effects of each 
locus rather than correlations with ancestry.  
Joint analysis using a mixed model approach is attractive because all participants are 
included irrespective of ancestry. Ideally, mixed model approaches control for population 
stratification by modelling distant relatedness between individuals due to ancestry (Sul et al., 
2018; Wojcik et al., 2019). Several implementations exist and some are listed in Supplementary 
Methods Section IV and Supplementary Table S4. Mixed models may yield greater statistical 
power, both through increased sample size and by controlling for the variance explained by the 
genetic relatedness between individuals (i.e., a random effects component; (Loh et al., 2018)). 
However, there is evidence that basic mixed models may not fully control for population 
structure in diverse cohorts, especially if there is an environmental component to phenotypic 
associations with ancestry beyond the modelled genetic relatedness (Conomos et al., 2018; 
Heckerman et al., 2016; Zhang and Pan, 2015). Non-genetic factors such as environmental 
exposures may be correlated with ancestry due to a shared local environment (familial or 
community effects) or due to the relationship between ancestry and socio-cultural factors such as 
race and ethnicity. More methodological development is needed before mixed models or other 
strategies for joint GWAS of a diverse cohort can be confidently recommended as robust. 
When stratifying by population backgrounds, covariates such as PCs should still be used 
to correct for population stratification. Conventional linear or logistic regression with these 
covariates can be used for association testing as long as QC included exclusion of related 
individuals; mixed models or other alternatives with PC covariates may be applied in family-
based samples stratified by ancestry (Walters et al., 2018). Computing these PCs separately 
within each ancestry subset instead of the full study ensures better control for residual structure 
specific to that subset (e.g., fine structure, genotyping/technical artifacts), but at the cost of 
potentially reduced control for stratification related to population structure shared across subsets 
(Patterson et al. 2006). For analyses of admixed or multi-ancestry cohorts, PCs may still be 
included in the regression but additional covariates may be required to control for stratification 
that is not linear in PCA space (Conomos et al., 2018; Heckerman et al., 2016; Zhang and Pan, 
2015). For example, race and ethnicity are often correlated with socio-economic status and other 
environmental risk factors for disease. Self-reported ethnicity or other variables that capture trait 
heterogeneity on the basis of socio-cultural factors may also be appropriate to consider as 
covariates in those instances (Banda et al., 2015; Medina-Gomez et al., 2015). Directly 
controlling for local ancestry tracts in variant-level association analyses may further improve 
power and reduce false positives in admixed samples (Li & Keating 2014). 
The meta-analysis approach, combining separate analyses of samples stratified by similar 
genetic background, currently has several pragmatic advantages. First, computational pipelines 
developed for single-ancestry analyses can be used for each cohort. Separate analysis also 
naturally provides ancestry-specific results, which may be valuable for secondary analyses 
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including PRS (Bulik-Sullivan et al., 2015; Lam et al., 2018). Reduced environmental variability 
within a subset may also improve power. On the other hand, splitting each cohort may be 
challenging due to continuous gradients of admixture or small sample sizes within an ancestry 
group. This loss of information from excluding individuals from diverse genomic backgrounds is 
a missed opportunity for discovery and validation of GWAS findings, and thus additional 
approaches need to be developed and leveraged.  
 
 
VI: Meta-analysis of GWAS Summary Statistics 
 
Traditional meta-analytic approaches for GWAS rely on fixed-effects models that assume a 
given variant has the same true marginal effect size across all studies. This assumption is likely 
to be violated in meta-analyses across diverse cohorts. Even when the causal genetic effect of a 
variant is constant across populations, as seems common in cross-ancestry GWAS to date 
(Huang et al., 2017; Lam et al., 2018), marginal effect sizes may show heterogeneity when LD 
structures are different. Further heterogeneity across cohorts from different populations may 
arise due to differences in genetic background (e.g., gene x gene interactions) and/or 
environmental context (e.g., gene x environment interactions), as well as differences in study 
design (e.g., imputation artifacts, phenotyping). As a result, it is generally appropriate to model 
this cross-cohort heterogeneity in meta-analysis by using a random effects or trans-ancestral 
meta-analysis model (Supplementary Methods Section 5, Supplementary Table S4). 
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Figure 2: Flow chart for QC, imputation, and association analysis in diverse population 
samples. 
This flowchart depicts the general analysis framework for genome-wide association studies of 
participants with diverse ancestral backgrounds. Note: boxes with red headers indicate analyses 
done in samples with diverse ancestral backgrounds and blue denotes analysis done within 
samples in major population groups. The left path shows a strategy for the stratified meta-
analysis approach and the right path shows steps for the joint mixed model approach (see 
Supplemental Table 2 for more detailed QC considerations). 
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VII: Fine-mapping 
 
A trait-associated locus from GWAS typically implicates a large genomic region with many 
variants of similar significance. This set may contain a few causal variants, while the association 
of other variants is driven by their LD with the causal one(s). Fine-mapping refines GWAS loci 
to a smaller set of likely causal variants to facilitate interpretation and follow-up studies (Schaid 
et al., 2018). Fine-mapping studies in samples of European ancestry have made important 
advances, with some loci resolved even to single-variant resolution (Huang et al., 2017; Mahajan 
et al., 2018). Because fine-mapping assumes the causal variant(s) have been observed, non-
European populations face a unique challenge due to the lack of representation of many variants 
as a result of incomplete sampling from these populations, suboptimal chip design, and limited 
imputation performance.  
Combining samples across ancestries has an advantage for fine-mapping: the LD patterns 
that differ across populations can improve the resolution, assuming that many causal variants are 
shared across populations, which has been shown true for some traits, including schizophrenia 
(Lam et al., 2018; Marigorta and Navarro, 2013; Wojcik et al., 2019). Non-causal variants 
tagging the causal variants have marginal different effects across populations if LD is different, 
thus allowing the causal variant to be distinguished from non-causal variants. Furthermore, in 
certain populations (e.g., African), LD blocks are generally smaller, so fewer non-causal variants 
will tag the causal variants, improving the resolution of fine-mapping (International HapMap 
Consortium, 2005; Schaid et al., 2018). 
Most fine-mapping algorithms (Huang et al., 2017; Schaid et al., 2018) can be applied to 
samples from multiple ancestries combined through meta-analysis. However, this strategy does 
not take full advantage of genomic diversity across populations. An alternate Bayesian fine-
mapping strategy (Lam et al., 2018) more precisely mapped the schizophrenia genetic 
associations through explicitly modeling diversity in LD between East Asian and European 
samples. This approach works on a presumption that the causal variants and their effect sizes are 
identical across populations, which is not always true. PAINTOR (Kichaev and Pasaniuc, 2015) 
relaxes this presumption by allowing the effect size to vary across populations, although the 
causal variant still needs to be the same. Fine-mapping methods will benefit from continued 
development that appropriately models LD and relies on fewer assumptions. 
 
VIII: Polygenic Risk Scores in Diverse Populations 
 
PRS are individual-level estimates of the relative genetic contribution to a phenotype, computed 
for each genotyped individual in a target sample based on GWAS results from a discovery 
sample. PRS are useful for validating GWAS results in external cohorts and have the potential to 
provide individualized risk prediction from genetic data (Khera et al., 2018; Martin et al., 2019). 
The predictive value of PRS profiling depends both on the statistical power of the discovery 
(training) dataset— specifically, enrichment in the genome-wide distribution of association test 
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statistics that is attributable to aggregate, additive genetic effects — and the relevant 
characteristics of the target (testing) dataset. 
In particular, PRS accuracy is also a function of recent human demographic history, such 
that a greater proportion of phenotypic variance is explainable in target populations that are 
genetically more similar to the population studied in the discovery GWAS. Stated another way, 
with increasing genetic “distance” between the discovery and target datasets, there is often  
attenuation of polygenic predictive value. Furthermore, because most participants in large 
GWAS have been broadly European (Figure 1), most PRS currently perform best in target 
samples of European ancestries, with markedly worse performance in other populations, 
especially in individuals of African descent (Duncan et al., 2018; Martin et al., 2019). 
  A practical question is how to construct polygenic scores for recently admixed 
individuals or individuals who are genetically distant from those in the largest existing GWAS. 
Use of trans-ancestry meta-analytic results to weight alleles can increase prediction accuracy 
(Grinde et al., 2019), and MultiPred is an approach that combines PRS based on European 
training data with PRS based on training data from the target population (Márquez-Luna et al., 
2017). Current methods development is focused on improving handling of allele frequency 
differences and LD within and across populations. Given current limitations in understanding 
similarities and differences in polygenic risk across populations, caution is advised in 
interpreting differences in PRS across ancestries (Novembre and Barton, 2018). 
 
 
IX: Heritability and Genetic Correlation 
 
GWAS can provide insights into the genetic architecture of human traits, including SNP 
heritability and genetic correlation. Several methods have been proposed for estimating these 
parameters from genotype data (Supplemental Table S4; Supplemental Methods Section V), 
but estimation and interpretation of these quantities is more challenging in diverse populations. 
Heritability estimates may differ between populations due to variation in both environmental 
factors and population genetic forces. Cross-population differences in phenotype measurement 
(Section XI) may further complicate interpretation. In evaluating shared genetic variance across 
populations, genetic correlation between groups can be defined either as the correlation of allelic 
effect sizes (genetic-effect correlation) or the correlation of the relative contribution to total 
phenotypic variance (genetic-impact correlation), and for all variants or for common variants 
present in a study. Each value is potentially informative, but divergence in allele frequencies and 
LD patterns between populations will lead to differences between these parameters (Galinsky et 
al., 2019). 
As detailed in the supplement, most common methods for estimating SNP heritability and 
genetic correlation either require modification or may not be suitable for use in multi-ancestry 
studies. Methods relying on relatedness estimation (e.g., genomic relatedness matrix restricted 
maximum likelihood; GREML) require estimation methods robust to population structure 
(Conomos et al., 2018; Thornton et al., 2012), and methods modelling LD (e.g., LD Score 
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regression; LDSC) require either ancestry-matched reference panels or individual level data for 
LD calculations (Luo et al., 2018). Ancestry-matched reference panels, along with the large 
GWAS sample sizes required for robust estimation using these methods, may be especially 
challenging to acquire for studies in underrepresented or admixed groups.  
Beyond these most common methods, local ancestry tracts in admixed population 
samples can be leveraged to estimate heritability (Zaitlen et al., 2014) and both genetic-effect 
and genetic-impact correlations of observed variants can be estimated using Popcorn (Brown et 
al., 2016) if LD information is available and the two populations are relatively homogeneous. 
Recent studies estimating cross-ancestry genetic effect correlations have found moderate to high 
correlations for most phenotypes (Bigdeli et al., 2017; Brick et al., 2019; Lam et al., 2018). The 
extent to which these cross-ancestry genetic correlations reflect consistent effects at any 
particular locus remains a question for fine mapping analyses.  
 
 
X: Rare Variant Association Analysis 
 
Rare SNPs and structural variants have been implicated in complex disease (Bomba et al., 2017). 
Due to their more recent origin, rare variants tend to be more geographically clustered and can be 
population specific. They can also be particularly important from both clinical and biological 
perspectives because some confer a large increase in disease risk. However, there is severely 
limited power to identify trait associations of individual rare variants. Therefore, aggregation 
methods such as burden tests, variance-component tests, and hybrid tests have been developed to 
test the combined effect of several variants. Using this approach, variants can be combined 
within genes or regulatory genetic elements (Gilly et al., 2018; Kuchenbaecker and Appel, 
2018). Ancestry groups may carry different driving variants at the same locus, as demonstrated 
by the association of different functional variants in ADH1B with alcohol use disorder in African 
Americans compared with European and Asian Americans (Edenberg and McClintick, 2018). 
Therefore, aggregate testing can be particularly suitable to projects involving different ancestral 
groups because they focus on functional units rather than individual variants and it is not 
necessary to observe the same variants or frequencies across cases. Meta-analysis methods have 
been developed that are able to encompass heterogeneous genetic effects across studies and are 
applicable to cross-ancestry meta-analysis (Lee et al., 2013; Tang and Lin, 2015).  
Association testing for rare variants is particularly sensitive to population stratification, 
and adjusting for fine-scale patterns of population stratification can be difficult with traditional 
methods (Zhang et al., 2013). In simulation studies, adjusting for PCs failed to fully control 
inflation for collapsing and variance-component methods (Persyn et al., 2018). Mixed effects 
models that have been developed for related samples might improve on this (Jiang and McPeek, 
2014). However, this area requires further methods development.  
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XI. Non-Genetic Contributors to Trait Variability 
  
Diversity in social, cultural, and environmental factors also affect disease risk, and can contribute 
to confounding in genetic studies. In the case of complex traits with strong environmental 
influences, such as psychiatric conditions, the need to account for non-genetic contributors to 
disease is important. Unfortunately, measurement of environmental factors can be difficult, so 
proxy measures such as zip code or insurance status can be used to model non-genetic risk 
factors such as air quality or accessibility to quality health care. PCs calculated from genotypes 
can control for population structure due to genetic relatedness, but this approach alone may not 
capture the social and environmental factors that are encompassed in self-reported “race” and 
“ethnicity”, even though these measures can be correlated with genetic ancestry. Self-reported 
measures of diversity can help in the modeling of societal determinants of health, such as 
increased stress due to the experience of racism and inequality and related variability in 
environmental factors (e.g., socio-economic status) that affect disease risk. However, the reliance 
on race and ethnicity as proxy variables for environmental effects or in order to control for 
population structure may be inappropriate. Better understanding and measurement of causal 
environmental risk factors is critical in order to advance discovery methods beyond these over-
simplified and potentially harmful constructs of non-genetic contributors to trait variability.  
Investigating complex traits in diverse populations, especially when samples are pooled 
from different research sites or cultural contexts, requires consistency and equivalence in the 
underlying construct and assessment measures across groups. Differences and variability in 
phenotypic measurement between study sites and populations may affect both gene discovery 
and the transferability of genetic findings between populations. Most psychiatric classification 
systems and diagnostic measures have been developed and validated in individuals from 
industrialized, Western societies (Henrich et al., 2010). This presents a substantial challenge for 
global and cross-cultural collaborations. Investigations into cross-cultural differences in the 
prevalence of major depression, for instance, have suggested that although there is a shared 
underlying disorder construct across groups (Kendler et al., 2015; Simon et al., 2002), 
individuals may differ culturally in terms of the level of symptomatology reached prior to 
seeking help (Simon et al., 2002). The inclusion and consideration of diverse populations in the 
development, validation, and deployment of diagnostic measures used in genetic studies is 
therefore critical for ensuring an unbiased picture of disease etiology (Supplemental Methods 
VII).  
Despite known large effects of environmental exposures on complex disease risk, there 
have been limited efforts to incorporate these factors into large-scale genetic studies. Appropriate 
modeling of the environment is especially critical when a phenotype or trait of interest is 
influenced by gene-by-environment interactions (GxE). That is, genetic risk factors not only 
alter average risk but also influence sensitivity to the effects of environmental adversities. 
However, the majority of GxE studies have been underpowered and conducted using samples of 
primarily European descent, which limits the assessment of GxE and thereby the identification of 
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modifiable targets for intervention and prevention among understudied groups (Duncan et al., 
2014). We note that the statistical definition of GxE depends on the choice of modelling on an 
additive or multiplicative scale (Kendler and Gardner, 2010). Greater representation of diverse 
individuals is critically needed in order to increase our understanding of how the interrelated 
contributions of genes and environment vary across social and cultural groups, and how these 
factors may interact. 
 
 
Box 3: Common pitfalls, recommendations, and methods in need of development. 
Method Pitfall Recommendation Needs 
Genotyping Many genotyping 
platforms do not cover 
non-European 
variation well. 
Use or design population-specific 
array or multi-ancestry array; high 
array density can improve 
coverage in groups with high 
diversity  
 
Consider low-depth whole-genome 
sequencing 
 
Continue improving coverage of 
diverse ancestries on genotyping 
arrays 
 
Encourage ongoing development 
and sharing of pipelines for 
analysis of low-depth sequencing 
data 
QC Unnecessary loss of 
data and/or incorrect 
inferences by using a 
one-size-fits-all 
approach 
See Figure 2 for specific 
recommendations for each QC step 
and Supplemental Table 2 
Improve availability and 
convenience of implementing 
proposed QC methods robust to 
population structure 
Imputation Inaccurate imputation 
due to poor matching 
of reference panel to 
sample 
Consider matching the ancestry of 
the reference panel as closely as 
possible to the sample ancestry if 
using a single ancestry sample. 
Consider the largest reference 
panel possible for imputation of 
multiple or admixed samples 
Continue expanding diversity of 
imputation panels,through 
collection of whole-genome 
sequencing data, creation of 
imputation panels from that data, 
and promoting public 
sharing/accessibility of those 
panels 
GWAS Poor control of 
population 
stratification 
Consider standard linear/logistic 
regression methods for analysis of 
single ancestry groups followed by 
meta-analysis. Consider mixed 
model approaches for admixed or 
multi-ancestry analyses 
 
Include PCs as covariates even 
when single ancestry groups 
analyzed. PCs should be computed 
individually for each major 
population group within a multi-
ancestry cohort and included as 
covariates in the regression model. 
Additional covariates should be 
considered for the multi-ancestry 
Continue investigating causes of - 
and solutions to - current 
incomplete control of population 
stratification from principal 
components and mixed models 
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analysis 
 
Meta-analysis False negative and 
false positive findings, 
effect heterogeneity 
Use a random-effects (with 
possible bias towards the null), or 
modified random-effects meta-
analysis model 
Continue to investigate and find 
solutions to improve power for the 
detection of heterogeneous effects 
 
Fine-mapping  LD improperly 
handled when all 
samples are meta-
analyzed across 
populations 
 
Uneven genome 
coverage across 
populations because of 
the genotyping array 
and the imputation 
reference panel  
Use fine-mapping methods that 
explicitly model population-
specific LD   
 
 
 
See recommendations for 
Genotyping and Imputation above 
Continue to develop fine-mapping 
methods that rely on fewer 
assumptions, and thoroughly 
evaluate their performance   
Polygenic risk 
scores 
Loss of accuracy in 
target population with 
increasing genetic 
distance from 
discovery cohort  
Extrapolation of PRS from one 
ancestry to another is problematic 
with current approaches and data 
Large discovery cohorts for all 
populations are needed. Develop 
methods for computing PRS that 
are not biased when applied across 
populations, potentially 
incorporating LD information 
and/or local ancestry information 
among diverse populations 
Rare variants Population 
stratification; low 
power to detect 
associations 
Aggregate tests can improve power 
and handle separate causal variants 
in different populations 
Approaches with better control of 
population stratification; more data 
on diverse populations needed  
Heritability 
estimates 
Differences in MAF 
and LD structures 
 
 
 
 
 
Different 
environments 
For GREML, use admixture-aware 
relatedness estimation for admixed 
samples 
 
For LDSC, consider using cov-
LDSC if in-sample genotype data 
is available 
Caution when comparing estimates 
between groups 
Currently no method based entirely 
on summary statistics can handle 
admixed/diverse samples. Evaluate 
options for developing estimation 
methods with reduced 
requirements for access to 
genotype data or ancestry-matched 
LD reference panels 
Cross-ancestral 
genetic correlation 
 
Requires large sample 
sizes and dense array; 
estimates influenced 
by genetic distance 
between groups 
Use Popcorn or GREML with 
admixture-aware estimation of 
genetic relatedness  
 
 
Improve robustness and user-
friendliness of software for 
summary statistics; increase 
diversity of LD reference panels  
Phenotypic 
measurement  
Lack of consideration 
of potential 
measurement 
differences across 
groups 
Consider and test for equivalence 
across populations. Be cautious 
when meta-analyzing or comparing 
across groups in which culturally 
sensitive measurement has not 
Interdisciplinary collaborations 
with local researchers across 
populations to continue developing 
and validating phenotypic 
measures 
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been demonstrated. 
GxE Lack of consideration 
of environmental 
factors that are 
relevant 
Consider environmental factors 
that may be of particular relevance 
to different socio-cultural groups 
(e.g., “racial/ethnic” 
discrimination).  
Consider running analyses 
separately for each group to gain 
understanding of GxE processes 
within populations, and be cautious 
when making comparisons across 
populations  
Large samples of diverse 
individuals and assessment of a 
broad range of environmental 
exposures and socio-cultural 
experiences  
 
 
 
Perspectives and Recommendations  
 
The lack of diversity in genetic studies is problematic for a variety of ethical and scientific 
reasons. Continued reliance on samples that only represent a fraction of genomic, socio-cultural, 
and environmental diversity limits our understanding of disease biology and may ultimately 
contribute to widening global health disparities. Greater ancestral diversity in study samples has 
the potential to accelerate the discovery of causal risk variants and is critical for a greater 
understanding of the biological causes of disease, including gene-by-environment interactions. In 
this primer, we have highlighted the challenges and benefits of working with diverse 
populations, recommended practices based on current methods, and have noted specific areas 
that are in need of further methodological development (Box 3). In summarizing progress, 
remaining challenges, and requisite next steps, we consider three main domains: 1) researcher 
participation, 2) data resources, and 3) analytic methods. 
 
Researcher Participation 
It is essential that cross-population research is carried out with careful consideration of its 
ethical, legal, and social implications (ELSI). This includes an ethos of trust-building, 
transparency, bi-directional knowledge sharing, and community engagement. This is especially 
true in low and middle income (LMIC) settings and in work with minority groups – contexts in 
which mistrust of researchers is warranted given historical mistreatment and ethical violations. 
As there is no single overarching legislative framework that covers this area, we draw attention 
to literature that (i) articulates key issues (e.g., consent-taking, data-sharing, sample governance, 
equal partnership, capacity building, community engagement, participants’ advisory boards 
(Akinhanmi et al., 2018; Claw et al., 2018; Parker and Kwiatkowski, 2016) and (ii) proposes 
effective working solutions to them (Beaton et al., 2017; Campbell et al., 2017; de Vries et al., 
2015). Additionally, there is a need to overcome traditional barriers to research empowerment 
for under-represented groups. H3ABioNet (https://www.h3abionet.org/), GINGER 
(https://ginger.sph.harvard.edu/), AMARI (https://amari-africa.org/), MIND (https://minds-
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uf.org/), and BRAIN (https://advance.washington.edu/brains) are examples of initiatives that 
embed the targeted delivery of skills and training within broader programs of research. 
Additional funding mechanisms that support such an approach would be particularly beneficial. 
 
Data Resources 
There is a critical need for extensive collaborative efforts to generate large-scale discovery 
cohorts of diverse ancestry. Limited diversity in genetics research is a major factor limiting our 
ability to address important scientific questions. The 1KGP (Sudmant et al., 2015) serves as one 
of the most widely-used resources in genetics research, but expanding those reference panels is a 
priority. Here, we provide a selected catalogue of extant and emerging sources of whole-genome 
sequence data (Table 1 and Supplemental Table S3), to facilitate improved matching of diverse 
study cohorts to appropriate reference panels. Notably, some sources of non-European data are 
under-utilized, such as minority groups within the UK Biobank. Although diverse ancestry 
groups only account for about 5% of this data, that fraction amounts to over 35,000 samples of 
non-European and admixed ancestry (Bycroft et al., 2018) and yet only 7.3% of publications 
since 2008 that used this data included any of these diverse samples. Thus, there are 
opportunities to make better use of these and other existing resources. 
Additionally, substantial efforts are needed for efficient and ethical international sample 
and data sharing. This is an issue under active debate, as countries have different approaches to 
weighing concerns about the privacy of individuals against the collective benefits of science, and 
the regulatory landscape of individual-level genotype data has been uneven. For example, while 
the UK allows open access of individual-level genotype data with a valid scientific proposal, 
other countries, such as Denmark, Iceland, and China, tightly regulate the sharing of such data. 
Some GWAS consortia, including the Enhancing NeuroImaging Genetics through Meta-Analysis 
(ENIGMA) and Social Science Genetic Association Consortium (SSGAC), overcame these 
regulatory challenges using essentially a “federated sharing model” (Fiume et al., 2019). Without 
sharing individual-level genotype data, a study in these consortia follows the prespecified 
analytic protocol and contributes its summary statistics to the meta-analysis, allowing the 
participation of studies that do not have permission to share individual-level data. Researchers 
should be aware of such options and restrictions, and we recommend regular review of policies 
as scientific advances may change the ground on which they are based. The practice of sharing 
summary statistics is increasingly important, and facilitates meta-analyses and other secondary 
analyses like polygenic risk scoring and estimation of cross-trait genetic correlations. Journals 
and funding agencies should require sharing of summary statistics whenever it is ethically and 
legally possible. 
 
Future directions for improving analytic methods 
Many of the analytic challenges involved in genetic studies of diverse populations (Box 3) can 
be addressed by recent advances in methodologies. We reflect on two key issues that remain 
unresolved and are likely to be beneficial directions for methodological development: 1) the 
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division of individuals into major population groups for analysis and 2) the extension of common 
secondary analyses of GWAS results to accommodate results from cross-population studies. 
A primary question currently faced in genetic analyses of diverse cohorts is whether to 
follow a ‘combining’ approach (analyzing all individuals together, regardless of ancestry) or a 
‘stratifying’ approach (dividing the cohort into major population groups for separate analysis, 
followed by cross-ancestry meta-analysis; Figure 2). Concerns regarding joint analysis methods 
(e.g., mixed models) include inadequate control for confounding population stratification and the 
limited options for secondary analyses such as polygenic risk scoring and genetic correlation 
estimates. To the extent that stratifying individuals into major population groups remains a 
feature of cross-population analyses, future methods and theoretical work may continue to refine 
standards for how best to assign individuals to more homogenous groups. The best solution 
currently available combines a priori analysis plans, exploratory examination of the data, and 
involving collaborators with expertise in analyzing globally representative datasets. Future work 
will benefit from increasing diversity in reference panels, formalizing how major populations 
should be defined for the purposes of genetic analyses, and evaluating the performance of such 
methods. Continued methodological work should help resolve the tension between these 
approaches, clarifying if and when stratifying samples is necessary and providing improved 
methods for joint analysis of diverse cohorts that addresses population stratification. 
Many post-GWAS statistical methods have limited portability to association results from 
diverse and admixed populations, due to complexities with LD patterns. Caution should be taken 
in the downstream analysis of cross-population GWAS meta-analyses, as many common 
approaches such as gene-based testing (e.g., MAGMA (de Leeuw et al., 2015)), heritability and 
genetic correlation estimation (e.g., LD Score regression (Bulik-Sullivan et al., 2015)), and 
predicted gene expression (e.g., S-PrediXcan (Barbeira et al., 2018)) rely on external reference 
panels that may not be compatible with the ‘combining’ approach. Even methodologies such as 
Popcorn (Brown et al., 2016) that are specifically designed for cross-population analyses 
typically assume single-population summary statistics as input. Furthermore, it is unclear 
whether annotations of GWAS results based on observed associations in external studies (e.g., 
gene expression, Hi-C contacts, methylation) may also need to evaluate population specificity or 
include diverse samples to improve generalizability across populations. For example, 85% of 
GTEx eQTL annotations are from individuals of European ancestry (GTEx Consortium, 2013) 
and other functional genomics resources may be similarly limited. 
The above-described methods of cross-population aggregation and comparison rely on an 
assumption that complex diseases are phenotypically similar across global populations and that 
measurement of such disorders is culturally unbiased. Given that we know these assumptions are 
not always accurate, the best practical steps are to be aware of potential phenotypic and 
environmental differences across populations and involve multi-disciplinary teams with expertise 
in global societal determinants of health and cultural competency. Suitable methods – such as 
those that account for cultural context of phenotype ascertainment and GxE – should then be 
developed and implemented to more precisely measure and treat disorders across cultures.  
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Conclusion 
There is a growing need for investment in policies and practices to support the inclusion of 
diverse research participants and thus maximize the global potential of genetics research and 
precision medicine. Broadening participation of both study populations and researchers from 
many regions of the globe and LMIC in particular will likely be tremendously beneficial. Within 
the arenas of available data and analytic methods, short-term goals include improved sharing and 
openness of data. Longer-term goals include identifying ways in which the complex practical, 
cultural, social, legal and ethical issues inhibiting sample collection from under-represented 
populations are best resolved. Early, often, and meaningful engagement of stakeholders from 
diverse patient groups and communities, multi-disciplinary investigators including those with 
expertise in community-based participatory research, research institutions, scientific editors and 
reviewers, and funding agencies will all be critical to the success of these short- and long-term 
objectives towards fostering an environment of inclusive research. Knowing that the lack of 
representation of diverse populations in genetics research will hinder our understanding of 
disease etiology, it is clear that this is both an important ethical and scientific growth area for 
genomics research. 
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